Dir of Med Affairs at Labcorp Oncology; Gyn Onc; Duke adjunct. Pet mom to 🐶🐶🐱🦔🐭🐓🐝; passionate about pollination, gardening & piano. Opinions are mine.
Durham, NC
Joined March 2017
- Tweets722
- Following497
- Followers1K
- Likes1.7K
Rebecca Previs retweeted
Comprehensive Genomic Profiling: A Required Tool for Precision Oncology @ASCO @ASCOPost @OncoAlert #ASCO23 @weoncologists
ascopubs.org/doi/10.1200/ADN…
Rebecca Previs retweeted
One more week until our live Ask the Expert Q&A with @Labcorp's @BeccaPrevisMD! Join us to learn how #personalized #medicine is transforming #breastcancer treatment and explore emerging targeted therapies for HER2-low breast cancer subtypes: us02web.zoom.us/webinar/regi…
ALT Outcomes4Me is hosting an Ask the Expert webinar series on the topic of "What is HER2-low and why should I get tested?" Tile showcases graphics, text, and Dr. Previs's headshot.
Rebecca Previs retweeted
Want to learn more about HER2-low breast cancer? Please tune into this webinar by my amazing colleague and oncologist, Dr. @BeccaPrevisMD as she leads important discussions around HER2-low breast cancer! 🙌🏻 – at San Antonio, TX
Join us for our upcoming Ask the Expert Q&A with @BeccaPrevisMD from @Labcorp where she'll discuss how personalized medicine is transforming breast cancer treatment and emerging targeted therapies for HER2-low breast cancer subtypes.
us02web.zoom.us/webinar/regi…
Rebecca Previs retweeted
👏🙌NRG GY018!! We did it - improved progression free survival in MMRd AND MMRp #EndometrialCancer. Standard of care == CHANGED! #SGOMtg #gyncsm #ImmunoOnc Congrats to @NRGonc
Check out @ElizabethABloom’s work today at #SGOMtg. She reports a molecular analysis of a retrospective cohort of patients with endometrial intraepithelial hyperplasia. 5% were dMMR; 4% were p53abn. @dukeobgyn #Previslab @KC_Strickland @pammiepeters @janicewon_ 🧪🔬👩🔬🧬
Mentoring is one of life’s greatest privileges—and it’s not about creating clones but giving the space for each to create themselves and their own authentic paths. Couldn’t be prouder of @pammiepeters and @ElizabethABloom. ⭐️ 👩🔬🔬🧬🧪#WomenInSTEM #sgomtg #PatientsPurposeProgress
Checkpoint inhibition has had limited efficacy in high grade epithelial cancer. So proud of @pammiepeters and her work evaluating MEM-288, a novel oncolytic adenovirus, demonstrating efficacy and generating a systemic immune response. #SGOMtg @dukeobgyn #PatientsPurposeProgress
Rebecca Previs retweeted
Our fellow Pamela Peters discussing her work on MEM-288 under mentor @BeccaPrevisMD proud of her work to improve the understanding of ovarian cancer immune response @dukeobgyn
The data are in! Cryocompression therapy works during chemo and prevents subjective neuropathy in patients with gyn cancers. Congrats @MKMontesDeOca @LHavrilesky and @dukeobgyn team. #SGOMtg #PatientsPurposeProgress
Thank you @Stigetta and @womenofteal for being a voice and a light. We are grateful for your advocacy, leadership, and reminding us of our purpose. #SGOMtg #PatientsPurposeProgress
Rebecca Previs retweeted
Standing room only for Dr. Britta Weigelt’s discussion of circulating tumor DNA! #SGO2023 @MSKPathology @SGO_org
Congrats to @DukeMedSchool’s @LindaM_Zambrano and her important work highlighting funding to lethality scores in patients with cancer. Despite its increase in mortality, #uterinecancer remains underfunded. This work informs policy change, advocacy and equitable funding. #sgomtg
Thanks to everyone who attended our @Labcorp Case Study presentation where we reviewed the clinical, morphologic, cytogenetic, and #molecular characteristics of a case with a TP53 biallelic alteration. #ASH22 @ASH_hematology
If you will be at the #ASH22 meeting next week, check out my @Labcorp teammate, @ESeversonMDPhD's presentation. 💜 the #ASHaiku! @ASH_hematology
Getting ready for the #ASH22 meeting with my #ASHaiku:
ASH workshop with me
December 10th, New Orleans
Hemepath with @Labcorp
@ASH_hematology
We analyzed ClinicalTrials,gov and found <10% of trials enrolling patients with gyn cancers report racial/ethnicity. We need diversity+transparency in enrollment. bit.ly/3Fdz49y @tomi_akinyemiju @MKMontesDeOca @BenPeipert @dukeobgyn @DukeCancer @Labcorp @ESeversonMDPhD
Rebecca Previs retweeted
Healthcare Access Dimensions and Guideline-Concordant #OvarianCancer Treatment: SEER-Medicare Analysis of the ORCHiD Study: jnccn.org/view/journals/jncc…
@MKMontesdeOca @BeccaPrevisMD @anjaligupta1680 @MariaPisu1 @MLiangMD @Kevin_C_Ward @AndrewBerchuck @tomi_akinyemiju
#hsronc #GynCSM
Congrats @MKMontesDeOca and Dr. Tomi Akinyemiju!
Rebecca Previs retweeted
We performed CGP on 3288 samples using @OmniSeqInsight’s NGS assay. We identified 16 NRG1 fusions – with an incidence of 0.4%. RNA sequencing increases the detection rate for NRG1 fusions and offers therapy options for patients. Visit our @Labcorp poster #AMPath22 #AMPlifier
Rebecca Previs retweeted
Check out poster #ST028 @AMPath today. @PGDx presents their validation study on plasma focus, an #NGS assay designed for solid tumor profiling from cfDNA. This assay reports SNVs/indels for 33 genes, amplifications in 8 genes, gene fusions in 5 genes and MSI. #AMPath22 #AMPlifier
